Oncology Products with Purpose
Our innovative approach to solving problems in oncology and for orphan indications ensures we bring products to market that ease the burden of use for caregivers and enhance patient outcomes.
We are dedicated to developing novel products that are clinically impactful focusing on the pharmaceutical formulation to ensure high quality, greater dose flexibility, easier administration and better acceptance of medicines.
Shorla Pharma have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (‘FDA’) on our oncology drug SH-105. The FDA’s prompt and definitive response confirms our clinical and regulatory strategy and aligns with our plan to accelerate the filing of our New Drug Application (‘NDA’).
Shorla Pharma have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (FDA) on our third oncology drug SH-110. This proprietary product will have a significant benefit to patients suffering from brain cancer ultimately reducing treatment burden and providing a palatable age appropriate treatment.
Shorla Pharma have submitted, and the US Food and Drug Administration (‘FDA’) have accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the company looks forward to working closely with FDA to bring this much needed product to market later this year.
By combining innovation and compassion, our pipeline contains products that make a difference to patients’ lives. Our product development strategy extends beyond specialty pharma and focuses on the end user, ultimately creating a pipeline with value and purpose.
This is where you place the text describing the work you are doing on this product.